BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Virbac Corporation (VBAC) to Distribute Prevtec Microbia, Inc.'s Innovative Coliprotec(R) Vaccine In Brazil


3/28/2011 7:10:14 AM

MONTREAL, March 28 /PRNewswire/ - Virbac, the 8th largest veterinarian pharmaceutical group worldwide, has concluded an exclusive Distribution and Trademark Licence Agreement with Prevtec microbia, a Canadian veterinarian laboratory, for the distribution of the Coliprotec® vaccine in Brazil.

Coliprotec® is a live bacterial vaccine developed by Prevtec microbia that prevents post-weaning diarrhea in pigs. Prevtec microbia recently secured government approval for the distribution of its first vaccine in Brazil, through its subsidiary, Prevtec microbia do Brasil. Virbac will be its exclusive distributor in this emerging country, which is the third largest producer of pork in the world. The contract with Virbac, concluded with the help of the Trifermed Group, is Prevtec microbia's first international distribution agreement.

Michel Fortin, President of Prevtec microbia stated "This distribution agreement with one of the largest pharmaceutical companies in the world, validates the quality of the work of the research team at Prevtec, a young Canadian agro-pharmaceutical company, which started operations only 5 years ago".

Thierry Gozlan, Area Director of Virbac Latin America, declared that this agreement will strengthen Virbac's already strong growth in Brazil, through its subsidiary, Virbac do Brasil Ltda. Coliprotec® also consolidates Virbac's recent entry into the market segment of food-producing animal vaccines.

Coliprotec® is a pure culture of non virulent E. coli bacteria, administered orally to piglets in their drinking water. A healthy alternative to antibiotics, it can be easily, safely and economically used for prophylaxis. Unlike antibiotics, the efficacy of Coliprotec does not reduce with use. "Coliprotec® perfectly fits Virbac's thrust towards promoting responsible use of veterinary medicines", said Thierry Gozlan.

Brazil a world class swine producer, is expected to increase its production and export and has undertaken to improve its production methods. "Being a vaccine, and not an antibiotic, Coliprotec® is in accordance with best practices in the care and feeding of food-producing animals and can enhance production performance", also stated Michel Fortin.

Founded in 1968 in Carros close to Nice (France), Virbac has become the world's first independent laboratory dedicated exclusively to animal health. With a turnover of €572.5 million in 2010, the company ranks today as the 8th largest veterinarian pharmaceutical group worldwide. Its wide range of vaccines and medicines for both companion and food-producing animals are appreciated by veterinarians and animal owners alike. Present in more than 100 countries, the company has more than 3150 employees.

Prevtec microbia is a Canadian company with offices in Montreal and Saint-Hyacinthe (Quebec) as well as in Saskatoon (Saskatchewan). Its mission is to develop new products and technologies to improve animal health and to increase performance in the production of food animals, such as pigs, poultry and cattle. The company has undertaken to get regulatory approval for Coliprotec® and two other of its products in several countries on three continents.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->